FDA Accelerates Psychedelic Drug Research Following Trump Executive Order
The FDA has announced measures to fast-track the development of psychedelic treatments for serious mental illnesses, including treatment-resistant depression and PTSD, following an executive order by President Trump. While the FDA emphasized that these drugs are not yet approved or proven safe, the move signals a shift in regulatory approach toward psychedelic-based medicines. The initiative includes priority vouchers for certain compounds and the authorization of early-stage clinical trials.
Topics: Clinical Trials FDA Mental Health Psychedelic Treatments Regulatory Approval